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ABSTRACT
INTRODUCTION Numerous studies have evaluated the efficacy and safety of 
varenicline for smoking cessation in smokers in the general population and, 
to a lesser extent, among the psychiatric population. However, few studies 
have evaluated varenicline in patients with other addictions. The present 
study was conducted to assess outcomes of a multimodal treatment for 
smoking cessation intervention with varenicline in a sample of alcohol and 
substance use disorders and patients with psychotic disorders.
METHODS This was a prospective, multicenter study. The patient sample 
comprised alcoholics in remission, methadone-maintained patients, and 
patients with psychotic disorders, all of whom wanted to stop smoking. All 
participants received multimodal treatment for smoking cessation therapy 
(psychological therapy plus varenicline). Smoking abstinence and changes 
in the psychopathological state of patients were assessed at predefined time 
points during a 12-month follow-up. The probability of tobacco abstinence 
after one year of treatment was computed using Kaplan-Meier life tables.
RESULTS The probability of abstinence at one year was 0.225 (95% CI: 0.143-
0.319). By group, the probabilities were as follows: patients with psychotic 
disorders 0.254 (95% CI: 0.118-0.415); alcoholics 0.237 (95% CI: 0.098-
0.409); and methadone-maintained patients 0.177 (95% CI: 0.065-0.335). 
Patients with previous quit attempts had a higher probability of achieving 
abstinence at one year (p<0.01).
CONCLUSIONS The results of this study support the use of multimodal treatment 
with varenicline in patients with alcohol addiction in remission, patients 
on methadone maintenance, and patients with stable psychotic disorders. 
Previous smoking cessation attempts were predictive of smoking cessation 
success in these patients.
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INTRODUCTION
Tobacco use is a risk factor in six of the eight 
leading causes of death in the world (World Health 
Organization, 2003). Worldwide, tobacco use kills one 
person every 6 seconds and reduces life expectancy 
by an average of 15 years1. Despite the significant 
decline in smoking prevalence in the general 
population in recent decades, the prevalence among 
psychiatric patients remains high. In a study with a 
North American population, the prevalence among 
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patients who had ever had mental illness is high (55% 
of lifetime smokers and 35% of current smokers2. 
The highest smoking rates are seen in individuals 
diagnosed with schizophrenia, mania, or depression3. 
Moreover, studies have shown that there is a direct 
relationship between the intensity of the psychiatric 
condition and the severity of the smoking habit4. 
Estimates suggest that 43-80% of alcohol abusers and 
49-98% of individuals with substance use disorders 
smoke cigarettes5.
Tobacco smoking causes considerable morbidity 
and mortality in patients with severe mental illness, 
with published reports suggesting that the high 
mortality rates associated with schizophrenia can 
largely be attributed to smoking6. Compared to 
the general population, people with severe mental 
illness are two to three times more likely to suffer 
from smoking-related illnesses such as cardiovascular 
disease or cancer7. 
Approved Food and Drug Administration (FDA) 
first-line medications for treating tobacco use 
include nicotine replacement therapies, bupropion 
SR, and varenicline8. However, these treatments are 
more effective when combined with psychological 
treatment. Systematic reviews confirm that treatment 
interventions based on behavioral support combined 
with pharmacotherapy are effective in the general 
population and in smokers with mental illness and 
addictive disorders9,10; importantly, these interventions 
do not appear to worsen psychiatric symptoms11.
Varenicl ine,  an alpha-4-beta-2 nicotinic 
acetylcholine receptor (nAChR) partial agonist12, 
was first commercialized in 2006 and has been 
approved by both the FDA and the European 
Medicines Agency (EMA). This receptor has been 
linked to the reinforcing effects of nicotine and to 
continued smoking behavior. Varenicline appears to 
partially reproduce the action of nicotine, with a dual 
mechanism of action, as it is a partial agonist with 
higher affinity but less functional effect than nicotine. 
As a result, varenicline may alleviate both craving 
and withdrawal symptoms during smoking cessation. 
In addition, if nicotine exposure occurs, varenicline 
would be expected to block the reinforcing effects of 
smoking by binding to the same receptor13. 
Several studies have assessed the efficacy and 
safety of varenicline and its relative effectiveness 
versus other drugs for smoking cessation. Varenicline 
is significantly more effective than placebo and 
more efficacious than bupropion and nicotine 
replacement therapy (NRT)14,15. The safety and 
efficacy of varenicline have been well-demonstrated 
in smokers in the general population and in those 
with smoking-related pathologies (e.g. cardiovascular 
disease and lung diseases)16,17. However, the benefits 
of varenicline in smokers with psychotic disorders 
were only recently confirmed with the publication of 
the randomized clinical trial conducted by Anthenelli 
et al.11, known as the EAGLES trial. Most studies 
conducted to date have involved patients without 
mental illness or addictions. In fact, the presence 
of these disorders is often considered exclusion 
criteria in clinical trials. In the EAGLES trial, at 24 
weeks follow-up, varenicline was more efficacious in 
achieving smoking cessation than nicotine patches, 
bupropion, or placebo. Notably, that study included 
patients with psychiatric disorders but excluded 
patients with drug use disorders within the previous 
12 months. Therefore, the efficacy of varenicline in 
patients with substance use disorders—who have 
a high prevalence of smoking and severe difficulty 
in quitting—remains unknown. A population-based 
study compared varenicline to nicotine replacement 
therapy and concluded that varenicline does not seem 
to be associated with a higher risk of depression or 
self-harm; however, that study used data from patients 
in the validated Q Research database and excluded 
patients who used drugs during the 12-month period 
prior to initiation of the study18. 
The process of quitting smoking, with or without 
medical treatment, has been associated with 
the emergence of psychiatric symptoms such as 
depression, dysphoria and anxiety, all of which are part 
of the nicotine withdrawal syndrome19. Importantly, 
smoking itself—particularly heavy smoking—has 
been closely linked to suicidal ideation and suicidal 
behavior in several studies20. 
Given the paucity of real-world data on the 
safety and efficacy of varenicline among psychotic 
patients, alcoholics, and patients with substance use 
disorders, we examined the outcomes of a smoking 
cessation program involving multimodal intervention 
(varenicline plus psychological treatment) after one 
year of follow-up. The sample included alcoholic 
patients in remission, patients on methadone-
maintenance programs, and patients with psychotic 
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disorders. We also sought to determine if this 
multimodal treatment was associated with changes in 
the psychiatric or addictive disorders of these patients. 
METHODS
Study design and subjects
This was a prospective, longitudinal study carried 
out at 11 specialized tobacco addiction units within 
the substance abuse treatment network of Catalonia, 
Spain. Participants were recruited from patients being 
treated at these centers who expressed a desire to quit 
smoking. Recruitment took place between September 
2008 and December 2009. Patients were included 
consecutively following their request to participate 
in the study.
A total of 90 patients with a confirmed diagnosis of 
nicotine dependence were recruited. All participants 
had a diagnosis of one of the following disorders: 
alcohol dependence disorder, opioid dependence 
disorder on methadone-maintenance, or psychotic 
disorder (schizophrenia, schizoaffective disorder, or 
chronic delusion). 
Inclusion criteria were: 1) ≥ age 18 years; 2) 
expressed a desire to quit smoking; 3) preserved 
cognitive abilities that allow to follow psychological 
therapy; 4) clinically stable (free of acute 
decompensation during the past 6 months); 5) 
stable pharmacological treatment for ≥ one month; 
and 6) active smoking habit of ≥ 10 cigarettes/
day during the 12 month prior to enrolment in 
the study. Exclusion criteria were: 1) diagnosis of 
other abuse or dependence disorders in the last 6 
months; 2) clinically significant medical disease 
in the preceding 6 months for which varenicline 
is contra-indicated; 3) previous history of suicidal 
behavior or presence of suicidal risk at screening; 
4) diagnosis of other DSM IV axis I psychiatric 
disorders; and 5) pregnancy.
Based on standard calculations, the required sample 
size was estimated to be 129 patients. However, only 
90 were included in our study, due to the limited 
budget assigned for this purpose by the Department 
of Health of the Government of Catalonia, which was 
funding the treatment.
The local ethics committees approved the study 
protocol. Patients were informed about the study 
protocol and provided written informed consent to 
participate in the study.
Measurements
Sociodemographic data were collected during 
the baseline interview. The following smoking 
characteristics were assessed: number of cigarettes 
smoked per day in the last month, years of smoking 
habit, and number of previous attempts to quit. 
We also registered all psychiatric diagnoses and 
current pharmacological treatments. Exhaled carbon 
monoxide (CO) was measured with the piCO+ 
Smokerlyzer® (Bedfont Scientific, Kent, England). 
Nicotine dependence was assessed with the 
Spanish version of the Fagerström Test for Nicotine 
Dependence (FTND). We gathered the patients’ level 
of motivation and confidence in their ability to quit 
smoking. The therapist asked them to score it in a 
visual analogue scale (VAS) ranging from 0 to 10. To 
measure the motivation, they were asked: ‘From 0–10 
mark the level of importance given by you to quitting 
smoking’, and to measure self-confidence: ‘From 0-10 
mark how confident you are you will quit smoking in 
the next months’. All variables described above were 
categorized for the data analysis (Table 1).
Abstinence, the main outcome variable, was 
measured at weeks 1, 2, 4, 8, 12, 26, 38 and 52 after 
‘quit day’ by self-reported smoking status and exhaled 
CO levels. Participants were considered abstinent 
when they reported not smoking any cigarettes in 
the last 7 days and when this was confirmed by a 
CO concentration <6 ppm21. At the end of the study 
in week 52, all were contacted to perform the CO 
measurement. Those who said they were abstinent 
made the measurement; only some of those who said 
they were smoking did not attend the visit at session 8.
At each follow-up visit, the therapist evaluated safety. 
Adverse events were monitored according to FDA 
Guidelines and classified on a scale ranging from 0-3; 
where 0=none, 1=mild, 2=moderate and 3=intense. 
Changes in the psychopathological state of patients 
were assessed. Modifications in pharmacological 
treatment for psychiatric pathologies and adherence 
to pharmacological treatment to quit smoking were 
monitored and recorded. The results regarding safety 
have been previously reported in detail22. 
Interventions
The intervention consisted of a 12-month multimodal 
individual treatment for smoking cessation, a 
standardized treatment approach that combines both 
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pharmacological and psychological interventions23. 
In all cases, clinical psychologists administered the 
intervention or by psychiatrists specialized in tobacco 
addiction. All the therapists were members of the 
Tobacco and Mental Health working group of the 
Catalan Network of Smoke-Free Hospitals and had 














Male 64 (71.1%) 18 (62.1%) 22 (73.3%) 24 (77.4%) 0.401
Female 26 (28.9%) 11 (37.9%) 8 (26.7%) 7 (22.6%)
Age (years)  mean (SD) 44.8 (10.1) 50.7 (10.5) 42 (7.3) 42 (9.8) 0.000
Physical illness, n (%) 0.031
No concomitant diseases 38 (46.3%) 11 (40.7%) 16 (59.3%) 11 (39.3%)
Cardiovascular disease 8 (9.8%) 6 (22.2%) 1 (3.7%) 1 (3.6%)
Respiratory disease 14 (17.1%) 5 (18.5%) 3 (11.1%) 6 (21.4%)
Cancer 2 (2.4%) 0 1 (3.7%) 1 (3.6%)
Infectious diseases 7 (8.5%) 1 (3.7%) 5 (18.5%) 1 (3.6%)
Others 13 (14.4%) 4 (14.8%) 1 (3.7%) 8 (28.6%)
Smoking characteristics
Duration of smoking (years) n (%) 0.005
<20 24 (27%) 3 (10.3%) 8 (26.7%) 13 (43.3%)
20−30 32 (36%) 8 (27.6%) 14 (46.7%) 10 (33.3%)
>30 33 (37.1) 18 (62.1%) 8 (26.7%) 7 (23.3%)
Cigarettes per day (last month) n (%) 0.026
<20 13 (14.4%) 6 (20.7%) 6 (20.7%) 1 (3.2%)
20−30 53 (58.9%) 17 (58.6%) 20 (66.7%) 16 (51.6%)
>30 24 (26.7%) 6 (20.7%) 4 (13.3%) 14 (45.2%)
Cigarettes per day,  mean (SD) 26.9 (10.8) 25.9 (10.8) 23.1 (9) 31.5 (11) 0.007
FTND* score n (%) 0.237
Low (≤4) 12 (13.5%) 2 (7.1%) 5 (16.7%) 5 (16.1%)
Medium (5–6) 25 (28.1%) 6 (21.4%) 12 (40.0%) 7 (22.6%)
High (≥7) 52 (58.4%) 20 (71.4%) 13 (43.3%) 19 (61.3%)
FTND* score, mean (SD) 6.9 (2.3) 7.2 (2) 6.2 (2.2) 7.2 (2.4) 0.237
Previous quit attempts, n (%) 0.272
0 32 (35.6%) 9 (31%) 15 (50%) 8 (25.8%)
1−2 41 (45.6%) 14 (48.3%) 12 (40%) 15 (48.4%)
>3 17 (18.9%) 6 (20.7%) 3 (10%) 8 (25.8%)
Previous quit attempts,  mean (SD) 1.3 (1.3) 1.4 (1.3) 0.8 (1) 1.7 (1.5) 0.034
Importance to quit score, n (%) 0.669
Low (≤5) 1 (1.1%) 0 0 1 (3.2%)
Medium (6−7) 5 (5.6%) 2 (6.9%) 2 (6.7%) 1 (3.2%)
High (≥8) 84 (93.3%) 27 (93.1%) 28 (93.3%) 29 (93.5%)
Importance to quit score, mean (SD) 8.6 (1.2) 8.6 (1.1) 8.6 (1.1) 8.6 (1.4) 0.669
Confidence to quit score, n (%) 0.042
Low (≤5) 21 (23.3%) 9 (31%) 5 (16.7%) 7 (22.6%)
Medium (6−7) 29 (32.2%) 3 (10.3%) 14 (46.7%) 12 (38.7%)
High (≥8) 40 (44.4%) 17 (58.6%) 11 (36.7%) 12 (38.7%)
Confidence to quit score, mean (SD) 6.1 (2.5) 5.9 (3.4) 6.4 (1.9) 6 (2.1) 0.042
*FTND: Fagerström Test for Nicotine Dependence
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participated in its clinical intervention Guide on the 
use of tobacco in patients with mental disorders, of 
which they were co-authors. The protocol applied 
for the psychological intervention was based on the 
Guide24, its content in line with the available scientific 
evidence. The Guide was authored by clinicians from 
almost all Catalan hospitals with mental health wards 
and was supported by the Department of Health of 
the Catalan Government. 
 All participants were scheduled for an initial visit 
to collect baseline clinical data, to discuss motivational 
strategies for smoking cessation, and to prescribe 
pharmacological treatment with varenicline, which 
began the day after the initial visit. Patients were 
expected to quit smoking within the 8th to 14th day 
after starting pharmacological treatment. This day 
was termed the ‘quit day’ or ‘D-day’. Pharmacological 
treatment with varenicline was administered for 12 
weeks, starting with an initial dose of 0.5 mg per day 
for 3 days, 0.5 mg twice a day from day 4 to 7, and 1 
mg twice a day for the following 11 weeks. 
In the next sessions, the therapist continued to work 
on the motivation for quitting and on relapse prevention 
strategies. The visit with the psychological intervention 
plus the monitoring lasted about 45 minutes. Specifically, 
the session was carried out in the following way: the 
patients completed a questionnaire before the visit where 
information was collected on tobacco consumption, 
pharmacological treatment, adverse effects, changes 
in psychiatric treatments and all the measures already 
described. Of the 45 minutes of the session, between 5 
and 10 minutes were devoted to reviewing these data 
and confirming abstinence by measuring CO, the rest 
were dedicated to motivation and prevention of relapse, 
according to the above-mentioned Guide.
The entire treatment regimen (pharmacological 
treatment and the psychological intervention) 
was delivered free to the patients. Varenicline was 
provided by the Department of Health (Public Health 
Directorate) of the government of Catalonia. The 
multimodal treatment was performed in public health 
centers of the Catalan network for mental health and 
addiction treatment.
Statistical analysis 
We used the Kaplan–Meier method to estimate 
cumulative abstinence (probability of continued 
abstinence and 95% CI) at one year.  We used Cox 
regression models to estimate the hazard ratios with 
95% CI for relapse at the end of the follow-up, after 
checking proportionality during follow-up. We used 
the Stata software program, v.14 (StataCorp; College 
Station, Texas; USA) for data analysis.
RESULTS
Sample characteristics
Of the 90 patients included in the sample, 29 
presented a disorder for alcohol dependence, 30 were 
patients addicted to heroin who followed a program 
of methadone maintenance, and 31 presented a 
psychotic disorder. 
Most of the patients (71.1%) in the three groups 
were males. The mean age of the patients was 44.8 
years. Among the three groups, the mean age of 
the alcoholic group (50.7 years) was significantly 
greater than the other two groups. There were no 
significant differences among the groups in terms of 
educational level: 22.3% did not complete primary 
school while 43.3% had a high school diploma. In the 
methadone-maintenance group, 50% of participants 
were employed versus 16.1% in the psychotic 
disorder group (64.5% of which received government 
assistance for their inability to work). 
Overall, 53.7% of the patients had some type of 
physical illness, the most common being respiratory 
disease (17.1%), cardiovascular disease (9.8%), 
and infectious disease (8.5%). In the methadone-
maintenance group, 59.3% of the patients had no 
physical illness, a significantly lower proportion than 
in the other groups (p=0.031). 
The mean number of cigarettes smoked per day in 
the overall sample was 26.9, with the highest number 
(31.5) observed in the psychotic disorder group. All 
of the patients were highly dependent on nicotine 
(mean FTND=6.9). The mean level of exhaled CO 
was 25.3 ppm. Most of the sample (64.5%) had made 
at least one serious previous attempt to quit smoking, 
although the patients in the methadone-maintenance 
group made significantly fewer quit attempts than 
patients in the psychotic disorder group (p=0.034). 
Overall, the sample had a mean motivation to quit score 
on the VAS (0 to 10) of 8.6 points, with a mean score of 
6.1 regarding confidence in their ability to successfully 
quit. The highest confidence levels were observed in 
methadone-maintenance patients and the lowest in the 
alcoholic group (p=0.042), as shown in Table 1.
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Quitting smoking 
At 52 weeks after the quit day, the probability of 
quitting smoking was 0.225 (95% CI: 0.143–0.319). 
The probability of quitting smoking at 1, 4 and 8 
weeks after the quit day, whilst still using varenicline, 
was 0.486 (95% CI: 0.379–0.584), 0.359 (95% CI: 
0.261–0.458) and 0.311 (95% CI: 0.219–0.410), 
respectively. Patients received varenicline for 12 
weeks after the quit day. The probability of abstinence 
at 12 and 26 weeks after quitting were, respectively, 
0.251 (95% CI: 0.166–0.346) and 0.225 (95% CI: 
0.143–0.318). Notably, this probability at week 26 
was the same as that observed at week 52 (Figure 1).
No relapses in psychiatric illnesses were observed 
in any of the patients who stopped smoking. 
The probability of successfully quitting smoking 
increased as a function of the previous attempts to 
quit, patients with more previous attempts had higher 
probability successfully quitting smoking (p<0.01), as 
shown in Table 2. 
Figure 1. Kaplan–Meier survival curves showing 






























Table 2. Probability of abstinence and hazard ratios for relapse at one-year follow-up
Variables Probability ( 95% CI) p Hazard ratio ( 95% CI)
Total 0.225 (0.143−0.319)
Diagnostic group 0.470
Psychotic disorder 0.254 (0.118−0.415) 1
Alcohol disorder 0.237 (0.098−0.409) 0.87 (0.48−1.58)
Methadone-maintenance 0.177 (0.065−0.335) 1.19 (0.67−2.12)
Sex 0.241
Male 0.250 (0.150−0.363) 1
Female 0.164 (0.052−0.332) 1.3 (0.78−2.18)
Smoking characteristics
Duration of smoking (years) 0.786
<20 0.208 (0.076−0.385) 1
20−30 0.237 (0.107−0.396) 0.83 (0.45−1.52)
>30 0.203 (0.083−0.360) 0.89 (0.49−1.61)
Cigarettes smoked per day last month 0.51
<20 0.192 (0.033−0.450) 1
20−30 0.244 (0.136−0.450) 1.11 (0.56−2.24)
>30 0.194 (0.065−0.376) 1.26 (0.58−2.72)
FTND* score 0.158
≤4 0.083 (0.005−0.311) 1
5−6 0.338 (0.161−0.523) 0.56 (0.258−1.211)
≥7 0.184 (0.088−0.307) 0.85 (0.435−1.651)
Previous quit attempts 0.0009
0 0.044 (0.003−0.183) 1
1−2 0.208 (0.098−0.347) 0.66 (0.39−1.10)
3−5 0.529 (0.276−0.730) 0.28 (0.12−0.63)
Continued
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The same occurred with multimodal treatment 
adherence, the patients who came at more sessions 
had a higher probability to quit smoking (p<0.01), 
shown in Table 2).
Adherence
Only 30 of 90 (33.3%) patients attended the 8 
sessions,  21 of which were abstinent at one year of 
follow-up. One patient of the 22 who were abstinent 
in week 52 attended seven sessions. The remaining 
nine patients relapsed before the 52 weeks of follow-
up. No differences in adherence were observed 
between diagnostic groups.
Group differences in the results 
At 52 weeks of follow-up, the highest rate of successful 
smoking cessation was observed in the psychotic 
disorder group, at 0.254 (95% CI: 0.118–0.415). 
By contrast, abstinence rates in the methadone-
maintenance and alcoholic groups were, respectively, 
0.177 (95% CI: 0.065–0.335) and 0.237 (95% CI: 
0.098–0.409), as shown in Figure 2.
The alcohol disorder group obtained the best initial 
results (i.e. at weeks 1–12) but a high percentage of these 
patients relapsed during the first three months, especially 
after the pharmacological treatment was completed. 
Results in the other two groups were more stable over 
time (Figure 2). There were no differences between 
groups in adherence to pharmacological treatment. 
Our team assessed the safety of varenicline in a 
previous study22. In the present study, we again 
evaluated safety, finding that varenicline was safe 
in this sample. The adverse events observed in the 
psychiatric disorder group in our sample were: dry 
mouth, flatulence, abnormal dreams, and nausea. 
According to diagnostic groups, the patients using 
methadone presented more adverse events than 
the alcohol group, but we did not observe other 
significant differences across diagnostic groups22. In 
our previous study, we reported that reducing the 
dose to 1 mg/day improved treatment adherence in 
patients who experienced adverse events and we also 
found that varenicline did not induce any significant 
exacerbations of psychiatric symptoms22.  
*FTND: Fagerström Test for Nicotine Dependence, CI: confidence interval.
Variables Probability ( 95% CI) p Hazard ratio ( 95% CI)
Importance to quit score 0.395
<5 0 1
5−7 0.300(0.123−0.719) 0.30 (0.31−2.94)
>7 0.225(0.141−0.321) 0.36 (0.04−2.66)
Confidence to quit score 0.140
<5 0.159 (0.040−0.348) 1
5−7 0.197 (0.075−0.360) 0.78 (0.41−1.46)
>7 0.277 (0.146−0.423) 0.60 (0.32−1.10)
Adherence to multimodal therapy 0.0000
<4 sessions 0 1
4−7 sessions 0.150 (0.037−0.334) 0.36 (0.19−0.70)
>7 sessions 0.417 (0.262−0.565) 0.15 (0.82−0.30)
ContinuedTable 2. 
Figure 2. Kaplan–Meier survival curves showing 
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DISCUSSION 
The aim of the present study was to determine the one-
year outcomes of a multimodal treatment for smoking 
cessation intervention consisting of varenicline plus 
psychological treatment in a sample of alcoholics in 
remission, methadone-maintenance patients, and 
patients with psychotic disorders. Our results show 
that this multimodal therapy can help patients with 
addictive and psychiatric disorders to quit smoking. 
Although the success rates in these patient groups 
were somewhat lower in the first weeks than observed 
in smokers in the general population11, the results at 
weeks 24 and 52 were similar16,25. 
Despite the relatively small sample size in this 
study, our results are consistent with those reported 
in studies with larger sample sizes. The EAGLES 
trial evaluated smoking cessation in a large sample 
(n=4074) of psychiatric patients, although patients 
with addictions were excluded in the EAGLES trial, 
continuous abstinence rates were 18.3% from weeks 
9–2411. Grant et al.26 evaluated smoking cessation 
in alcoholic patients, reporting abstinence rates of 
24% at week 4 and 21% at week 9; notably, their six 
months results (22%) were similar to our outcomes 
(22.5%). Hurt et al.27 recently published a study 
with a smaller sample than ours but with similar 
conclusions, varenicline is safe and efficacious for 
increasing smoking abstinence rates in smokers with 
alcohol abuse or dependence.
By contrast, Nahvi et al.28 evaluated 70 methadone-
maintained patients treated with varenicline, reporting 
an abstinence rate at six months of only 8.6%; while 
the reason for this lower rate compared to ours is 
not clear; it may be at least partially due to the type 
of psychotherapy offered in multimodal approach 
given that Nahvi et al.  administered the same 
pharmacological treatment.
Compared to the EAGLES trial, the patient sample 
in our study had more severe psychopathological 
disorders and a greater level of tobacco dependence. 
However, the samples in both studies achieved 
similar abstinence rates during the pharmacological 
treatment phase, which decreased sharply in both 
studies after finalization of pharmacological treatment. 
This finding supports the efficacy of varenicline in 
these patient populations, although it is worth noting 
that varenicline was somewhat less effective in these 
patients than in the general population.
Hitsman et al.29 concluded that the combination 
of cognitive behavioral therapy with motivational 
strategies and pharmacotherapy could improve 
smoking cessation outcomes in patients at mental 
health centers. Our findings confirm this conclusion, as 
we achieved good outcomes by using a comprehensive 
treatment approach (i.e. a multimodal intervention) 
at all participating centers. In our treatment program, 
all of the treating therapists were either psychologists 
or psychiatrists with extensive training in psychiatric 
pathology and addictions. In addition, the treatment 
centers were all reference centers for psychiatry, 
addictions, and smoking cessation. The participating 
centers were members of the working group on 
mental health and smoking, promoted by the Catalan 
Network of Smoke-Free Hospitals, and are thus 
especially prepared and motivated to provide smoking 
cessation aid to mental health patients. 
One impediment to improving the outcomes 
of smoking cessation programs is the difficulty of 
standardizing non-pharmacological interventions. 
Numerous studies have evaluated pharmacological 
treatments, but few have assessed the different 
types of psychological interventions, and even 
fewer have investigated the influence of using a 
combined approach involving both pharmacological 
and psychological interventions. The present study 
adds valuable data, but additional observational or—
ideally—randomized controlled studies are needed to 
better assess the factors described by Hitsman et al.29.
Few studies have evaluated tobacco cessation 
in methadone-maintained patients. However, the 
studies carried out to date in this population have 
reported six-month cessation rates of 5.2%30, 5.4%31 
and 8.6%28; by contrast, we obtained a cessation rate 
of 17.7%. Perhaps our results are better due to the 
multimodal treatment, although it is difficult to make 
a comparison between studies when talking about 
psychological intervention, because many of them do 
not explain what type of intervention they perform.
Patients in the methadone group participate in a 
harm reduction program, but have not gone through 
the process of giving up the addictive substance 
and therefore would not benefit from the relapse 
prevention experience of alcoholic patients. Several 
studies suggest that the experience of giving up one 
drug is useful when trying to give up other drugs26. 
Continued drug use, even if the drug is methadone, 
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may interfere with patients’ cognitive abilities and 
brain neurochemistry, making it harder for them to 
achieve and maintain abstinence32.
An important finding of our study is that, of all 
the patient-related baseline variables, the number of 
previous smoking cessation attempts was the strongest 
predictor of success, a finding that is consistent 
with previous reports33. However, the factors that 
trigger quit attempts in this population are poorly 
understood and more studies are needed to better 
characterize the factors that motivate multiple quit 
attempts. Motivation, as other authors reported34, or 
aspects related to skill acquisition, could be among 
the factors that facilitate quitting smoking and also 
prevent relapses. Whatever the relevant factor, it 
seems reasonable to point out that interventions that 
promote quit attempts may improve the likelihood of 
mid- to long-term smoking cessation.
Study strengths and limitations
The main limitation of this study is the small sample 
size. Nevertheless, our findings were consistent with 
those obtained in studies involving larger sample sizes, 
such as the EAGLES trial and others11,26. Another 
potential limitation is the risk of variation in treatment 
due to the multicenter study design (11 different 
centers and a large number of therapists). Although 
the intervention was standardized by a common 
protocol, some therapist-related and location-related 
differences are possible. However, these differences 
are common in real-world clinical practice. In fact, 
a strength of this study is that it was conducted in a 
real clinical environment. Moreover, this study is one 
of the few to assess the efficacy of varenicline in an 
addicted population. Moreover, the one-year follow-
up is longer than most other studies, which usually 
have a shorter follow-up period, lasting only until the 
end of pharmacological treatment. Moreover, we also 
measured exhaled CO levels to verify patient-reported 
abstinence. Finally, because the drug treatment was 
fully funded and closely monitored, we were able to 
closely assess treatment adherence, which is not always 
the case, due to the economic cost of the treatment, 
in a real-world environment such as a clinical setting 
that can confound results. 
CONCLUSIONS
The results obtained in this study support the use 
of multimodal treatment with varenicline in patients 
with alcohol addiction in remission, patients on 
methadone maintenance, and patients with stable 
psychotic disorders. Previous smoking cessation 
attempts were predictive of smoking cessation success 
in these patients. The high smoking prevalence rates 
in these patient populations impose a high burden in 
terms of morbidity and mortality. For this reason, it is 
essential to better identify the factors that would most 
likely improve the outcomes of smoking cessation 
treatments in these patient populations.
*Tobacco Group of the Catalan Network for Addiction Treatment:
Montse Ballbè, Margarita Cano, Blanca Carcolé, Teresa Fernández, Àngela 
Martínez, Sílvia Mondon, Gemma Nieva, Cristina Pinet, Antònia Raich, Pilar 
Roig, Imma Serra, Jaume Serrano.
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